- FDA approves Upsher-Smith's Qudexy XR extended-release capsules
- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
SILVER SPRING, Md. — Pregnant mothers taking a common drug for treating epilepsy may be putting their babies at risk, according to a new report from the Food and Drug Administration.
The FDA said Friday that the drug topiramate could increase the risk for such birth defects as cleft palate and cleft lip when used by expectant mothers. Johnson & Johnson markets the drug under the name Topamax, and it is available in generic form.
“Healthcare professionals should carefully consider the benefits and risks of topiramate when prescribing it to women of childbearing age,” FDA Division of Neurology Products director Russell Katz said. “Alternative medications that have a lower risk of birth defects should be considered.”